| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:51 UTC |
|---|
| Update Date | 2022-03-07 02:51:51 UTC |
|---|
| HMDB ID | HMDB0015057 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Buprenorphine |
|---|
| Description | Buprenorphine, also known as buprenorfina or temgesic, belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene. In humans, buprenorphine is involved in the buprenorphine action pathway. Buprenorphine is a primary metabolite. Primary metabolites are metabolically or physiologically essential metabolites. They are directly involved in an organism’s growth, development or reproduction. Based on a literature review a significant number of articles have been published on Buprenorphine. |
|---|
| Structure | CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4 InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (-)-Buprenorphine | ChEBI | | 17-Cyclopropylmethyl-4,5alpha-epoxy-7alpha-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol | ChEBI | | 2-(N-Cyclopropylmethyl-4,5alpha-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6alpha-yl)-3,3-dimethyl-2-butanol | ChEBI | | 2-[3-Cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol | ChEBI | | 21-Cyclopropyl-7alpha-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine | ChEBI | | Buprenorfina | ChEBI | | Buprenorphinum | ChEBI | | Temgesic | Kegg | | 17-Cyclopropylmethyl-4,5a-epoxy-7a-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol | Generator | | 17-Cyclopropylmethyl-4,5α-epoxy-7α-((S)-1-hydroxy-1,2,2-trimethylpropyl)-6-methoxy-6,14-endo-ethanomorphinan-3-ol | Generator | | 2-(N-Cyclopropylmethyl-4,5a-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6a-yl)-3,3-dimethyl-2-butanol | Generator | | 2-(N-Cyclopropylmethyl-4,5α-epoxy-3-hydroxy-6-methoxy-6,14-endo-ethanomorphinan-6α-yl)-3,3-dimethyl-2-butanol | Generator | | 21-Cyclopropyl-7a-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine | Generator | | 21-Cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavine | Generator | | Buprenophine | HMDB | | Essex brand OF buprenorphine hydrochloride | HMDB | | Key brand OF buprenorphine hydrochloride | HMDB | | Reckitt benckiser brand OF buprenorphine hydrochloride | HMDB | | Buprex | HMDB | | Temgésic | HMDB | | Buprenorphine hydrochloride | HMDB | | Grünenthal brand OF buprenorphine | HMDB | | Reckitt and colman brand 2 OF buprenorphine hydrochloride | HMDB | | Buprenex | HMDB | | Reckitt and colman brand 1 OF buprenorphine hydrochloride | HMDB | | Schering plough brand OF buprenorphine hydrochloride | HMDB | | Buprenorphine grünenthal brand | HMDB | | Prefin | HMDB | | RX-6029-m | HMDB | | Schering-plough brand OF buprenorphine hydrochloride | HMDB | | Grünenthal brand OF buprenorphine hydrochloride | HMDB | | Hydrochloride, buprenorphine | HMDB | | RX 6029 m | HMDB | | Reckitt brand OF buprenorphine hydrochloride | HMDB | | Subutex | HMDB |
|
|---|
| Chemical Formula | C29H41NO4 |
|---|
| Average Molecular Weight | 467.6401 |
|---|
| Monoisotopic Molecular Weight | 467.303558805 |
|---|
| IUPAC Name | (1S,2R,6S,14R,15R,16R)-3-(cyclopropylmethyl)-16-[(2S)-2-hydroxy-3,3-dimethylbutan-2-yl]-15-methoxy-13-oxa-3-azahexacyclo[13.2.2.1²,⁸.0¹,⁶.0⁶,¹⁴.0⁷,¹²]icosa-7,9,11-trien-11-ol |
|---|
| Traditional Name | buprenorphine |
|---|
| CAS Registry Number | 52485-79-7 |
|---|
| SMILES | CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4 |
|---|
| InChI Identifier | InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1 |
|---|
| InChI Key | RMRJXGBAOAMLHD-IHFGGWKQSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as phenanthrenes and derivatives. These are polycyclic compounds containing a phenanthrene moiety, which is a tricyclic aromatic compound with three non-linearly fused benzene. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Benzenoids |
|---|
| Class | Phenanthrenes and derivatives |
|---|
| Sub Class | Not Available |
|---|
| Direct Parent | Phenanthrenes and derivatives |
|---|
| Alternative Parents | |
|---|
| Substituents | - Phenanthrene
- Azaspirodecane
- Tetralin
- Coumaran
- Alkyl aryl ether
- 1-hydroxy-2-unsubstituted benzenoid
- Aralkylamine
- Piperidine
- Tertiary alcohol
- Tertiary amine
- Tertiary aliphatic amine
- Dialkyl ether
- Ether
- Oxacycle
- Azacycle
- Organoheterocyclic compound
- Organooxygen compound
- Organonitrogen compound
- Organic nitrogen compound
- Alcohol
- Organopnictogen compound
- Hydrocarbon derivative
- Amine
- Organic oxygen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | Not Available | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 0.017 g/L | Not Available | | LogP | 3.8 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Experimental Collision Cross Sections| Adduct Type | Data Source | CCS Value (Å2) | Reference |
|---|
| [M+H]+ | CBM | 209.7 | 30932474 |
|
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 6.13 minutes | 32390414 | | Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 5.92 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 12.0628 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 3.37 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 56.2 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 2430.2 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 146.1 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 217.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 148.0 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 131.2 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 724.7 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 529.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 233.6 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 1012.8 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 482.9 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 1391.0 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 355.3 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 351.2 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 212.9 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 211.7 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 8.1 seconds | 40023050 |
Predicted Kovats Retention IndicesDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Buprenorphine,1TMS,isomer #1 | CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O[Si](C)(C)C)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5 | 3222.4 | Semi standard non polar | 33892256 | | Buprenorphine,1TMS,isomer #2 | CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O[Si](C)(C)C)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5 | 3278.0 | Semi standard non polar | 33892256 | | Buprenorphine,2TMS,isomer #1 | CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O[Si](C)(C)C)C(C)(C)C)[C@H]1CC4=CC=C(O[Si](C)(C)C)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5 | 3276.8 | Semi standard non polar | 33892256 | | Buprenorphine,1TBDMS,isomer #1 | CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O[Si](C)(C)C(C)(C)C)C(C)(C)C)[C@H]1CC4=CC=C(O)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5 | 3470.2 | Semi standard non polar | 33892256 | | Buprenorphine,1TBDMS,isomer #2 | CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=CC=C(O[Si](C)(C)C(C)(C)C)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5 | 3509.4 | Semi standard non polar | 33892256 | | Buprenorphine,2TBDMS,isomer #1 | CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O[Si](C)(C)C(C)(C)C)C(C)(C)C)[C@H]1CC4=CC=C(O[Si](C)(C)C(C)(C)C)C5=C4[C@@]3(CCN1CC1CC1)[C@H]2O5 | 3723.8 | Semi standard non polar | 33892256 |
|
|---|